Quarterly Appendix 4C and Activities Report
Released
Released
Announcement PDF
27 October 2023
ASX Announcement
QUARTERLY ACTIVITIES REPORT – SEPTEMBER QUARTER 2023
Quarter highlights
•
New AD-214 data supports potential efficacy of intravenous (IV) product and
points way to a potential subcutaneous (SC) product for the future
•
AD-214 Phase I extension clinical study commenced with AD-214 well tolerated
at target Phase II doses
•
Significant progress on multiple partnering initiatives with high near-term impact
potential
•
$3.57 million cash position as at 30 September 2023 ($4.79 million as at 30 June
2023); terms of Victorian Government R&D Cash Flow Loan Facility extended
MELBOURNE Australia, 27 October 2023: AdAlta Limited (ASX:1AD), the clinical stage
company developing novel protein and cell therapeutic products from its i-body® platform,
generated important new data during the September quarter supporting the efficacy the
target intravenous (IV) version of AD-214 in fibrotic diseases such as Idiopathic Pulmonary
Fibrosis (IPF). In addition, the Company identified a potential next generation
subcutaneous (SC) version of AD-214 and generated further safety data supporting use of
AD-214 at likely Phase II clinical study doses. These results support accelerating
partnering momentum on multiple fronts. The Company reports a cash balance of
$3.57 million as of 30 September 2023.
Reflecting on the quarter, AdAlta’s CEO and Managing Director, Dr Tim Oldham
commented:
“The September quarter of 2023 was all about generating new AD-214 data that materially
de-risks the asset. Armed with new tools to predict efficacious doses and a continuing
favourable safety profile at higher AD-214 doses we are in a much stronger partnering
position. We are aggressively pursuing both out-licensing and fully funded co-development
collaborations to progress AD-214 into Phase II clinical trials. If we are able to successfully
convert any of the pipeline of collaborations these could deliver a material financial impact
for AdAlta in the near term.
A. Operations overview
1. AD-214 value proposition for partners strengthened
Priority: generate return on investment by securing non-dilutive financing of Phase II
clinical studies that realises value created by AdAlta
AdAlta’s lead product, AD-214, is a first in class, next generation antibody therapeutic for
the treatment of fibrotic diseases including lung fibrosis (specifically Idiopathic Pulmonary
Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some
cancers. The Company’s priority is to progress Phase II clinical studies in IPF or kidney
fibrosis through partnerships, and in doing so realising the value created by the investment
to date in this asset.
New preclinical data enables prediction of efficacious doses at commercially viable dosing
regimens – supports IV doses selected for Phase II clinical studies and identifies potential
SC doses.
To be successful, any new drug must be safe and effective at a dosing regimen that can
actually be used in a real-world clinical setting and at doses that allow for a competitive
cost of goods. Market research and potential partner feedback shows that an IPF drug
administered IV requires at least two weeks between doses (because patients are
reluctant to attend IV clinics more frequently). On the other hand, SC administration (which
can be done by the patient at home) is more likely to be adopted if given on a weekly
regimen (it is easy to remember and minimizes the number of times a patient must selfinject).
Prior to the September quarter, AdAlta had demonstrated that AD-214 was efficacious in
multiple animal models of fibrosis at multiple doses, and that it was well tolerated in healthy
volunteers when administered intravenously every two weeks in a Phase I clinical study.
What was not known was whether the level of target receptor occupancy (or blocking) by
AD-214 that could be maintained over two weeks by IV infusion could be efficacious.
As shown schematically in Figure 1, AdAlta has now closed this knowledge gap. Early in
the quarter, the Company announced new preclinical data that for the first time linked
levels of receptor occupancy with inhibition of immune cell migration, a surrogate model
of the fibrotic process. This showed that the levels of target receptor occupancy observed
in Phase I clinical studies two weeks after IV infusion at 10 mg/kg and higher could be
efficacious.
In a next step, AdAlta used existing Phase I data to develop a model to predict receptor
occupancy over time for any IV infusion regimen. The model was then adapted to also
predict receptor occupancy following a variety of SC regimens.
The most important conclusions, were:
1. AdAlta’s target IV AD-214 product, a 10 mg/kg infusion every two weeks, was likely
to be efficacious
2. A next generation SC AD-214 product, a 3mg/kg injection once per week, might
also be efficacious, offering greater patient convenience and lower cost of goods.
Figure 1: New AD-214 data validates commercially viable product design
2
The IV findings enable improved design and significantly reduced risk of Phase II clinical
studies of AD-214. Partner feedback confirms that the potential for SC administration
significantly improves commercial potential, adding significant value to the asset.
Following completion of the current Phase I extension studies, AdAlta anticipates that a
partner would progress IV AD-214 into Phase II studies as the fastest and most costeffective way to demonstrate clinical efficacy. In parallel, the work to develop a SC
formulation and progress it through Phase I studies could be completed. Subject to the
success of each development stream, partners would then have the option of progressing
either IV or SC AD-214 into Phase III trials necessary for registration.
Phase I extension study adds further value, continues to strengthen safety profile
of AD-214
During the quarter the Company commenced a Phase I extension study to evaluate the
safety and tolerability of multiple doses of IV AD-214 at 10 mg/kg.
Eight participants have now received three doses of AD-214 or placebo. Clinical
investigators have reported that AD-214 was well tolerated at these higher doses, with no
dose limiting toxicity, no need to interrupt doses and no requirement to administer
medication to manage infusion reactions. The frequency of mild infusion related reactions
appears lower than that observed at lower doses in the original Phase I study.
Full pharmacokinetic and receptor engagement analysis can now commence and remains
on schedule for discussion with partners in November 2023. The additional data points will
enable the dose finding simulations to be updated. The study participants will receive a
final dose (twelve weeks after the 3rd dose) with the aim of confirming that there is no
immune response to AD-214 that might affect efficacy and safety. Full safety and
tolerability results are due in the March Quarter of 2024.
AdAlta supports Bill van Nierop and Long Kayak for Lungs 2
During the quarter, AdAlta was pleased to support IPF survivor, Bill van Nierop, as he
undertook the Long Kayak for Lungs 2, a 1,440 km kayak expedition down the
Murrumbidgee River. Bill was diagnosed with IPF in 2015 and was fortunate to receive a
rare double lung transplant in 2021, the only cure for IPF today, making Bill one of the rare
survivors of IPF. He is a tireless campaigner for greater investment in research and
awareness of and support for IPF patients. This was Bill’s third major expedition to raise
funds for the cause of IPF. More about Bill’s journey can be found at:
https://www.longkayakforlungs.com.au/.
2. Partnered immuno-oncology programs continue to progress
i-CAR-T with Carina Biotech
AdAlta is now working on three targets under its i-CAR-T collaboration with Carina Biotech
(Carina). In vivo proof of concept studies of A-i-CAR-T cell candidates targeting an
undisclosed tumour antigen “A” are progressing. AdAlta has now commenced discovery
activities against two additional tumour antigen targets with the eventual objective of
creating CAR-T cells with capability to target both antigens.
3
GZMB-i-PET imaging with GE Healthcare
AdAlta continues to collaborate with GE Healthcare to develop i-body enabled granzyme B
PET imaging agents for use in immuno-oncology with positive progress made on several
work streams during the quarter. Further updates for this program will be provided in
consultation with GE Healthcare and as milestones are achieved.
GPCR heterodimers combinations with GPCR Therapeutics
GPCR Therapeutics is continuing evaluation of several CXCR4 i-bodies under the
collaboration announced in October 2022 with continuing favourable results.
3. Corporate and business development initiatives offer near term upside
AdAlta is progressing three partnering streams to unlock near term value from its assets
and reduce financial risk to shareholders. The identity of potential partners and progress
of any partnering program cannot be disclosed, however anonymized examples illustrate
the significant momentum building behind all streams.
Stream 1 - AD-214 Phase II out-licensing or co-investment: secures Phase II development
and generates a return on AdAlta’s investment to date
The objective of this stream is to either:
•
•
Out-license AD-214 to a larger biopharmaceutical partner who would undertake
further development of AD-214. AdAlta would then receive milestone payments
and royalties on eventual sales; or
Co-develop AD-214 with a partner who co-invests in the AD-214 project, providing
the funds necessary to complete Phase II clinical studies. AdAlta would likely
receive reimbursement of historical expenses and contributions to overhead costs
and retain substantial ownership of AD-214
As described in the June 2023 quarterly report, following the Bio Industry Organisation
BIO2023 partnering conference, AdAlta identified 21 potential licensing partners actively
evaluating AD-214 and willing to consider a transaction prior to Phase II. During the
quarter, the Company advanced some discussions, elected not to proceed with others and
opened new discussions. By way of example, one biopharmaceutical company began
testing samples of AD-214 in its in-house assays, noting that if AD-214 successfully
passed this screen they would likely commence full due diligence.
AdAlta has also fielded a number of enquiries seeking the opportunity to co-invest in the
AD-214 project. Examples include a clinical research organisation proposing to invest part
or all their Phase II clinical trial fees in the project, through to strategic or financial investors
seeking private investments with single asset exposure through a clinical inflection point.
AdAlta has engaged additional advisors to help evaluate and progress these opportunities.
A common theme from all potential partners has been a positive response to AD-214’s
novel model of action, the quality of AdAlta’s in vitro mode of action investigations and the
potential for multiple routes of administration. The most common questions being asked
in due diligence are being addressed by the data and dose simulation model developed
during the September quarter or by the ongoing Phase I extension study.
4
Stream 2 - i-body® platform licensing: licensing of AdAlta’s inventory of i-body® discovery
programs or co-discovering i-bodies against new targets expands pipeline at reduced cost
This stream aims to replicate the collaborations with GE Healthcare, Carina Biotech and
GPCR Therapeutics to partially or fully fund new discovery programs to fully leverage the
unique capabilities of the i-body® platform, generating a return for AdAlta with substantially
reduced capital at risk. The Company targets applications leveraging the i-body® ability to
go where antibodies cannot and focusses on multi-functional cell therapy applications and
G-protein coupled receptor (G-PCR) targets.
The value of a broad “inventory” of i-body discovery programs and well characterised
i-bodies (and by implication our in house research team) was exemplified by progress
made on one of these during the quarter. At BIO2023 in June, AdAlta received three
unsolicited expressions of interest in an early discovery stage i-body program. A small
molecule against the target had just achieved encouraging Phase II results and a
preclinical antibody program had recently been acquired for more than US$100 million. A
rapid outreach campaign by our business development team generated a further six
requests for further information that are now being evaluated.
Stream 3 - Accessing complimentary products and intellectual property: could expand
AdAlta’s clinical pipeline and enhance the reach of the i-body® platform
To ensure AdAlta maintains and grows a robust pipeline of assets, a fourth partnering
stream is continuously evaluating opportunities to in-license or acquire assets and
technology platforms in, or approaching clinical trials, and where there are clear synergies
with the i-body platform and existing skills. The company is evaluating more than five
assets at any given time.
4. Intellectual property
AdAlta continues to evaluate opportunities to expand intellectual property protection for its
technology. During the quarter the Company filed a new patent application claiming
methods of treatment using AD-214 which if granted would confer additional protection to
2043.
5
5. Near term milestones
AdAlta’s milestones and data read-outs for the next six months include:
Status as at 30
Jun 2023
Status as at 30
Sep 2023
On track (Aug’23)
Achieved
On track (Q4’23)
On track
(Nov’23)
On track (Q4’23)
Early Jan’24
Q1’23
On track
In vivo proof of concept results of A-i-CAR-T cells
On track (H2 2023)
Q1’24
Discovery programs for targets B and C continue
Commencing
On track
Goal
AD-214
First HV participant first visit for AD-214 Phase I
extension clinical study
First HV headline results from AD-214 Phase I
extension clinical study
Final HV participant visit for AD-214 Phase I
extension study
Full safety and tolerability results for AD-214
Phase I extension study
Carina collaboration
B. Corporate and organisation updates
During the quarter, the Company completed the placement of a Shortfall Facility under a
non-renounceable pro rata Rights Offer to AdAlta shareholders in Australia and New
Zealand (Eligible Shareholders) to acquire 2 new ordinary shares (New Shares) at an issue
price of 2.5 cents ($0.025) per New Share for every 5 shares held by Eligible Shareholders
together with 1 option (New Option ASX:1ADOA) for every 2 New Shares subscribed for.
Each New Option entitles the holder to subscribe for 1 additional ordinary share at an
exercise price of 3 cents ($0.03) per share with an expiry date of 29 May 2024.
The Shortfall Facility under the Rights Offer was over-subscribed and after scale back
raised $1.87 million, bringing the total raised under the Rights Offer to $3.15 million. This
resulted in the issue of 74,846,752 New Shares together with 37,423,362 New Options to
subscribers for the New Shares under the Shortfall Facility as well as a further 15,000,000
options to the corporate advisor for the Rights Offer on the same terms as the New Options.
During the quarter, 100,000 unlisted options were issued under the Company’s Omnibus
Equity Plan and 450,000 options were cancelled due to expiry or the vesting conditions
becoming unable to be met.
C. Financial position
Operating cash outflows for the quarter were A$2,822,872 (A$2,063,237 in the prior
quarter). The outflows increased largely due to R&D expenditure associated with
completion of manufacturing of AD-214 for toxicology studies commenced in the first half
of 2023 and the commencement of the Phase I extension clinical study. The manufacturing
costs will not be repeated in the December quarter.
6
AdAlta maintains a $4.0 million loan facility under the Victorian Government R&D Tax Cash
Flow Incentive scheme (Facility). The Facility was fully drawn on 30 September 2023. As
announced on 18 October 2023, the Company received a $2.35 million RDTI rebate in
respect of the FY23 year. $2.0 million will be used to partially repay the Facility and the
repayment terms of the Facility have been amended as described in item 7.6 of the
Appendix 4C accompanying this report.
The cash balance at the end of the quarter was A$3.57 million, (A$4.79 million at the end
of the previous quarter). The Company is actively evaluating and progressing multiple
activities to raise additional funds, including out-licensing AD-214 and the i-body platform,
project financing ongoing development of AD-214 and capital raising.
In accordance with Listing Rule 4.7C, payments made to related parties and their
associates included in item 6.1 of the Appendix 4C were ($166,957) which include Director
fees plus the salary (including superannuation and short-term incentive payments) for the
CEO and Managing Director.
Authorised for lodgement by:
Tim Oldham
CEO and Managing Director
October 2023
Notes to Editors
About AdAlta
AdAlta Limited is a clinical stage drug development company headquartered in Melbourne,
Australia. The Company is using its proprietary i-body® technology platform to solve
challenging drug targeting problems and generate a promising new class of single domain
antibody protein therapeutics with the potential to treat some of today’s most challenging
medical conditions.
The i-body® technology mimics the shape and stability of a unique and versatile antigen
binding domain that was discovered initially in sharks and then developed as a human
protein. The result is a range of unique proteins capable of interacting with high selectivity,
specificity and affinity with previously difficult to access targets such as G-protein coupled
receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully
human single domain antibody scaffold and the first based on the shark motif to reach
clinical trials.
AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is
being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human
fibrotic diseases for which current therapies are sub-optimal and there is a high unmet
medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a
second target in discovery research, also in the field of fibrosis and inflammation.
The Company is also entering collaborative partnerships to advance the development of
its i-body® platform. It has a collaboration with Carina Biotech to co-develop precision
engineered, i-body® enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients
with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic
7
imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immunooncology drugs, a program now in preclinical development.
AdAlta’s strategy is to maximise the products developed using its next generation i-body®
platform by internally discovering and developing selected i-body® enabled product
candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering
with other biopharmaceutical companies to develop product candidates against other
classes of receptor, in other indications, and in other product formats.
Further information can be found at: https://adalta.com.au
For more information, please contact:
Investors
Media
Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au
IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au
8
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
ADALTA LIMITED
ABN
Quarter ended (“current quarter”)
92 120 332 925
30 September 2023
Consolidated statement of cash flows
Current quarter
$A’000
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Year to date
(3 months)
$A’000
-
-
(1,757)
(1,757)
(b) product manufacturing and operating
costs
-
-
(c) advertising and marketing
-
-
(d) leased assets
-
-
(e) staff costs
(605)
(605)
(f)
(434)
(434)
-
-
(a) research and development
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
16
16
1.5
Interest and other costs of finance paid
(43)
(43)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
-
-
1.8
Other (provide details if material)
-
-
1.9
Net cash from / (used in) operating
activities
(2,823)
(2,823)
2.
Cash flows from investing activities
2.1
Payments to acquire:
(a) entities
-
-
(b) businesses
-
-
(63)
(63)
(d) investments
-
-
(e) intellectual property
-
-
(c) property, plant and equipment
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
(f)
2.2
other non-current assets
Current quarter
$A’000
Year to date
(3 months)
$A’000
-
-
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
Proceeds from disposal of:
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
(63)
(63)
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
1,872
1,872
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
-
-
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
-
-
3.7
Transaction costs related to loans and
borrowings
(153)
(153)
3.8
Dividends paid
-
-
3.9
Other – (provide details if material)
(56)
(56)
3.10
Net cash from / (used in) financing
activities
1,663
1,663
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
4,790
4,790
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
(2,823)
(2,823)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(63)
(63)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
4.5
Effect of movement in exchange rates on
cash held
4.6
5.
Current quarter
$A’000
Year to date
(3 months)
$A’000
1,663
1,663
-
(5)
Cash and cash equivalents at end of
period
3,567
3,567
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
Previous quarter
$A’000
5.1
Bank balances
443
903
5.2
Call deposits
3,124
3,887
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
3,567
4,790
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
167
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
-
Current quarter
$A'000
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of,
and an explanation for, such payments
The amount at 6.1 includes Director fees and CEO and Managing Director salary (including superannuation and
short term incentive).
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
4,000
4,000
7.1
Loan facilities
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
-
-
7.4
Total financing facilities
4,000
4,000
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
-
Loan facility in place as at 30 September 2023 is a non-dilutive funding facility of up to $4.0million with
Treasury Corporation of Victoria (TCV) as part of the Victorian Government’s R&D Cash Flow Loan Initiative.
The Facility was received in two tranches: the first of $2.4 million was received in September 2021; and the
second of $1.6 million was received in the quarter ending 31 March 2022. As at 30 September 2023 the total
loan facility was $4.0million, being fully drawn.
As anticipated in an announcement on 18 October 2023, the repayment terms of the Facility have been
amended. The table below outlines the original terms and the amended terms of the Facility as agreed by
AdAlta Limited and TCV.
Original terms
Facility amount as at date
of announcement
Repayment
$4,000,000
Endorsed
Terms
$4,000,000
Amended
100% by 31 October 2023.
Timed to coincide with receipt
of FY2023 RDTI
50% by 31 October 2023
15% by 31 January 2024
35% by 30 April 2024
Interest rate
TCV 11am loan interest rate
(currently 4.265%)
TCV 11am loan
(currently 4.265%)*
Security
FY2022 and FY2023 RDTI
refund
FY24 RDTI refund
interest
rate
* Any overdue instalment payments may also attract an additional 2% interest.
$2.0 million of the facility will be repaid from the $2.35 million RDTI rebate received 18 October 2023.
8.
Estimated cash available for future operating activities
$A’000
8.1
Net cash from / (used in) operating activities (Item 1.9)
(2,823)
8.2
Cash and cash equivalents at quarter end (Item 4.6)
3,567
8.3
Unused finance facilities available at quarter end (Item 7.5)
8.4
Total available funding (Item 8.2 + Item 8.3)
8.5
Estimated quarters of funding available (Item 8.4 divided by
Item 8.1)
3,567
1.3
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
8.6
If Item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net
operating cash flows for the time being and, if not, why not?
Answer: During the quarter ending 30 September 2023 the company incurred significant
R&D costs in relation to the completion of manufacturing activities and the
commencement of the Phase 1 extension clinical study. The manufacturing
component will not continue in the December 2023 quarter.
Further, as announced on 18 October 2023 the Company received its FY23 R&D
tax incentive refund of $2,350,940 of which $2.0million will be used to make the first
repayment of the TCV loan under an extended repayment schedule, resulting in a
net cash increase of $0.35 million.
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise
further cash to fund its operations and, if so, what are those steps and how
likely does it believe that they will be successful?
Answer: The Company is actively evaluating and progressing multiple activities to raise
additional funds, including out-licensing AD-214 and the i-body platform, project
financing ongoing development of AD-214 and capital raising. It has engaged
specialist advisers to assist with each of these initiatives, including Just Partnering,
Grannus Securities and Peak Asset Management.
8.6.3
Does the entity expect to be able to continue its operations and to meet its
business objectives and, if so, on what basis?
Answer: As outlined above, the Company has engaged a number of advisors to assist with
its multiple business and corporate development initiatives.
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
27 October 2023
...................................................................................
The Board
Authorised by: ...................................................................................
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash
Share your feedback
Discover